Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To assess the safety and effectiveness of ezetimibe co-administered with any statin [atorvastatin, rosuvastatin or simvastatin] compared to doubling of current statin daily dose in south Asian Canadians

Next Previous
Search
Trial Profile

To assess the safety and effectiveness of ezetimibe co-administered with any statin [atorvastatin, rosuvastatin or simvastatin] compared to doubling of current statin daily dose in south Asian Canadians

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezetimibe (Primary) ; Atorvastatin; Rosuvastatin; Simvastatin
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 27 Jul 2011 Planned end date changed from 1 Apr 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.
    • 27 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Dec 2009 Schering-Plough merged with Merck-and-Co hence Merck-and-Co added as trial sponsor as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top